After moving to accelerate a confirmatory clinical trial of the Alzheimer’s drug Aduhelm, Biogen (NSDQ:BIIB) plans on selling its equity stake in the Samsung Bioepis joint venture for up to $2.3 billion. The deal would give Biogen $1 billion in cash and $1.25 billion to be paid in two installments after that. In addition, Biogen…